Literature DB >> 8418762

Measurement of factor VIII. A potential risk factor for vascular disease.

J T Brandt1.   

Abstract

Factor VIII is a critical component of the coagulation system that is necessary for activation of factor X by factor IXa. Decreased levels of factor VIII are known to be associated with an increased risk of bleeding. It has been suggested that increased levels of factor VIII may be associated with thrombosis and atherosclerosis. Review of published studies indicates that the relationship between an increase in the level of factor VIII and atherosclerosis remains unclear at this time. While there is evidence that patients with atherosclerosis may have an increased levels of factor VIII, it is unclear if this is a primary or secondary event and whether such an increase is predictive of clinical outcome. The interpretation of epidemiologic studies is made more difficult by the current status of clinical laboratory assays for factor VIII activity. Interlaboratory proficiency surveys continue to show relatively high interlaboratory imprecision for these assays. These surveys have documented that a number of laboratories still use suboptimal methods for factor VIII assays and that use of these suboptimal methods is associated with poor performance. Improvement in factor VIII assay performance may be necessary before the role of factor VIII in atherosclerosis can be clearly defined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418762

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  2 in total

1.  [Effect of exercise tolerance test on hemostasis in patients with and without coronary heart disease].

Authors:  M Lins; T Arendt; A Deutschmann; O Dieszbrock; U Steen; H D Bruhn
Journal:  Med Klin (Munich)       Date:  2000-01-15

2.  Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.

Authors:  Ryan J Summers; Shannon L Meeks; John F Healey; Harrison C Brown; Ernest T Parker; Christine L Kempton; Christopher B Doering; Pete Lollar
Journal:  Blood       Date:  2011-01-07       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.